Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Browsing Category
HHS-OIG
HHS OIG: Proposed Budget for FY 2014
We previously wrote about President Obama’s FY 2014 budget for the U.S. Department of Health and Human Services (HHS) and its…
OIG Special Fraud Alert – Physician Owned Distributors
OIG recently published a Special Fraud Alert on physician-owned entities that derive revenue from selling, or arranging for the…
HHS OIG Report on Medicare COI Finds Potential for Conflict But No Actual…
Federal law and regulations require Medicare Part D Pharmacy and Therapeutics (P&T) committees to make prescription drug…
HHS OIG Report: FDA Lacks Comprehensive Data to Determine Whether Risk…
The Office of the Inspector General (OIG) for the Department of Health and Human Services (HHS) released a report, which asserts…
HHS OIG: Listing of Pharmaceutical and Device Corporate Integrity…
Below is a list in alphabetic order of the major pharmaceutical and medical device manufacturer corporate integrity agreements…
Amgen Settlement and Corporate Integrity Agreement
Adding to the long list of pharmaceutical settlements involving off-label promotion, Amgen Inc., the world’s largest biotechnology…
HHS OIG Solicits Input on Safe Harbor Provisions
The Office of the Inspector General (OIG) for the Department of Health and Human Services (HHS) recently released a Notice in the…
2012 HHS OIG Semiannual Report to Congress
The Office of Inspector General (OIG) for the Department of Health and Human Services (HHS) recently released its Semiannual…
United States v. Caronia: A Victory for Free Speech vs. Off Label Promotion
The United States Court of Appeals for the Second Circuit (New York), in a 2-1 opinion, vacated the criminal conviction of a…
HHS Office of Inspector General: Top Management and Performance Challenges…
Annually, the Office of Inspector General (OIG) prepares a summary of the most significant management and performance challenges…